Feasibility of Pisum sativum as an expression system for pharmaceuticals.
Based on its high protein content and excellent storage capacity, pea (Pisum sativum), as well as other plants, is considered to be a suitable production platform for protein-based pharmaceuticals. Its capacity to produce high proportions of active recombinant proteins (up to 2% total soluble protein corresponding to approximately 8 mg/g fresh weight) has been proven using pea-derived strong seed-specific promoters. The active antigens produced were also stable for more than 4 years. Pea can be used as a feed additive, up to a proportion of 30% to total feed, despite the presence of lectins. Thus, a low dosage of recombinant pea-based pharmaceuticals is non-hazardous. In addition, it is independent of N-fertilisation, has excellent biosafety characteristics and is accessible to gene transfer. Growth systems with a capacity for high yield are available for the greenhouse (5 t/ha) and, to a limited extent, also in the field (2.3 t/ha). The practicable establishment of pea seed banks allows a continuous production process. Although the use of a pea system is limited by complex transformation procedures, these advantages render pea a promising plant for the production of pharmaceuticals.